KindredBio Announces Filing of an Investigational New Animal Drug Application for KIND-002

KIND-002 is expected to be a major new therapy for severe cutaneous diseases in dogs​ SAN FRANCISCO, California. (February 3, 2013) – Kindred Biosciences, Inc. (KindredBio) announced today the filing of an Investigational New Animal Drug Application (INAD) with the U.S. Food and Drug Administration (FDA) for KIND-002. KIND-002 is a potent molecule being developed […]

KindredBio Elects Ervin Veszprémi, Former Global Head of Marketing for Novartis Animal Health, to Its Board of Directors

Highly Regarded Veterinary Marketing Executive to Join KindredBio’s Board SAN FRANCISCO, California, (January 22, 2013) – Kindred Biosciences, Inc., (KindredBio) a biotechnology company focused on developing therapies for companion animals, today announced that Mr. Ervin Veszprémi will be joining the company’s Board of Directors.